Vistagen Therapeutics financials
$0.2980+0.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jun 30 | Q4 '26 Mar 31 | Q3 '26 Dec 31 | Q2 '26 Sep 30 | Q1 '26 Jun 30 | Q4 '25 Mar 31 | Q3 '25 Dec 31 | Q2 '25 Sep 30 | Q1 '25 Jun 30 | Q4 '24 Mar 31 | Q3 '24 Dec 31 | Q2 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $465.0K | $303.0K | $258.0K | $244.0K | — | $234.0K | $183.0K | $84.0K | $197.0K | $411.0K | $278.0K |
| Gross profit | $1.5M | $465.0K | $303.0K | $258.0K | $244.0K | — | $234.0K | $183.0K | $84.0K | $197.0K | $411.0K | $278.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$13.3M | -$16.7M | -$19.5M | -$20.1M | -$15.8M | — | -$15.1M | -$14.2M | -$12.1M | -$11.4M | -$7.9M | -$6.8M |
| Net income | -$13.0M | -$16.3M | -$18.9M | -$19.4M | -$15.1M | — | -$14.1M | -$12.9M | -$10.7M | -$9.5M | -$6.3M | -$6.6M |
| Net margin | −882.8% | −3499.8% | −6237.3% | −7520.9% | −6186.5% | — | −6020.9% | −7071.6% | −12777.4% | −4833.0% | −1545.0% | −2369.8% |
| Diluted EPS | $-0.30 | $-0.38 | $-0.45 | $-0.54 | $-0.47 | — | $-0.46 | $-0.42 | $-0.35 | $-0.31 | $-0.22 | $-0.66 |
| EBITDA | -$13.3M | -$16.7M | -$19.5M | -$20.0M | -$15.8M | $40.0K | -$15.1M | -$14.2M | -$12.1M | -$11.3M | -$7.9M | -$6.7M |
| Operating cash flow | -$14.7M | -$16.2M | -$17.6M | -$13.8M | -$18.8M | -$10.1M | -$10.3M | -$10.9M | -$10.9M | -$7.0M | -$4.7M | -$6.2M |
| Free cash flow | -$14.7M | -$16.2M | -$17.7M | -$13.8M | -$18.9M | -$10.2M | -$10.3M | -$10.9M | -$10.9M | -$7.0M | -$4.8M | -$6.2M |
| Diluted shares | 43.0M | 42.4M | 42.2M | 35.7M | 31.9M | 31.6M | 30.7M | 30.6M | 30.6M | 30.7M | 29.4M | 10.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.0M | $30.8M | $47.4M | $62.8M | $49.0M | $67.1M |
| Short-term investments | $14.7M | $14.6M | $14.4M | $14.4M | $14.2M | $13.4M |
| Total debt | $0.00 | $96.0K | $379.0K | $658.0K | $933.0K | $0.00 |
| Total assets | $35.7M | $48.6M | $65.1M | $80.9M | $68.9M | $84.3M |
| Total liabilities | $11.3M | $13.0M | $14.1M | $14.6M | $12.2M | $14.0M |
| Shareholders' equity | $24.5M | $35.5M | $50.9M | $66.3M | $56.8M | $70.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology